Novartis’ Phase III misses, pharma deals analysis, MFN carve-outs — a BioCentury podcast

• Novartis and Lp(a) fallout — Pelacarsen's Phase III failure has shaken confidence in a genetically supported cardiovascular target and ignited a debate over whether issues with the target, modality or treatment setting contributed to the lack of efficacy.

• Pharma dealmaking strategy — Large pharmas are expanding deal activity and leaning harder into disruptive platforms such as bispecifics, in vivo CAR Ts, siRNAs, and degraders to secure competitive advantage in high-value markets...